AMENDMENT

Please amend the application as follows:

In the specification:

Please replace the paragraph of page 26, lines 20 to 24, with the following rewritten paragraph:

B1 The RGD-luciferase was also injected into a nude mouse with an orthotopic mammary tumor. Luciferin was administered. The animal was imaged in an *in vivo* bioluminescent imaging system. As shown in Figure 2, the presence of the tumor was detected by the emission of luciferase-produced photons from the tumor site (see arrow).

In the claims:

Please add the following new claims:

--70 (NEW) A method for *in situ* or *in vivo* imaging of a cell, a tissue, an organ or a full body comprising administration of a pharmaceutical formulation in an amount sufficient to enhance the image, wherein the pharmaceutical formulation comprises a composition comprising a chimeric molecule and a pharmaceutically acceptable excipient, wherein the B2 chimeric molecule comprises a first domain comprising a bioluminescent or chemiluminescent polypeptide and a second domain comprising an RGD motif-comprising polypeptide, and the formulation is suitable for administration as an imaging enhancing agent and the chimeric molecule is present is an amount sufficient to enhance a computer assisted tomography (CAT) image, a magnetic resonance spectroscopy (MRS) image, a magnetic resonance imaging (MRI) image, a positron emission tomography (PET) image, a single-photon emission computed tomography (SPECT) image or a bioluminescence image (BLI).

71. (NEW) A method for *in situ* or *in vivo* imaging of a cell, a tissue, an organ or a full body comprising the following steps:

(a) providing a pharmaceutical formulation comprising a chimeric molecule and a pharmaceutically acceptable excipient, wherein the chimeric molecule comprises a first domain